Vitamin, mineral, and drug absorption following bariatric surgery

Current Drug Metabolism

Volumn 13, Issue 9, 2012, Pages 1345-1355

  Sawaya, Ronald Andari ^a   Jaffe, Jane ^a   Friedenberg, Lindsay ^a   Friedenberg, Frank K ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bariatric; Drug malabsorption; Gastric bypass; Vitamin deficiency

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; ATORVASTATIN; BACLOFEN; BETA LACTAM ANTIBIOTIC; BIGUANIDE; CIMETIDINE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE; FAMOTIDINE; GABAPENTIN; INDINAVIR; METFORMIN; METHOTREXATE; MINERAL; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RANITIDINE; SALICYLIC ACID; SAQUINAVIR; SIMVASTATIN; TACROLIMUS; THROMBIN INHIBITOR; TRACE ELEMENT; UNINDEXED DRUG; VERAPAMIL; VINBLASTINE; VITAMIN;

ALPHA TOCOPHEROL DEFICIENCY; BARIATRIC SURGERY; BILIOPANCREATIC BYPASS; CALCIUM DEFICIENCY; CYANOCOBALAMIN DEFICIENCY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG PENETRATION; DRUG SOLUBILITY; DRUG TRANSPORT; FOLIC ACID DEFICIENCY; GASTRIC BANDING; HUMAN; INTESTINE ABSORPTION; IRON DEFICIENCY; MACRONUTRIENT; MORBID OBESITY; PROTEIN DEFICIENCY; RETINOL DEFICIENCY; REVIEW; ROUX Y ANASTOMOSIS; SLEEVE GASTRECTOMY; UNITED STATES; VITAMIN D DEFICIENCY; VITAMIN K DEFICIENCY; VITAMIN SUPPLEMENTATION; ZINC DEFICIENCY;

ANIMALS; BARIATRIC SURGERY; HUMANS; INTESTINAL ABSORPTION; MINERALS; OBESITY, MORBID; PHARMACEUTICAL PREPARATIONS; VITAMINS;

EID: 84868012130     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920012803341339     Document Type: Review

References (124)

1. Ogden, C.L.; Carroll, M.D.; Flegal, K.M. Epidemiologic trends in overweight and obesity. Endocrinol. Metab. Clin. North. Am., 2003, 32, 741-760.
2. Ogden, C.L.; Carroll, M.D.; Curtin, L.R.; Lamb, M.M. Prevalence of High Body Mass Index in US Children and Adolescents, 2007-2008. JAMA, 2010, 303, 242-247.
3. Flegal, K.M.; Graubard, B.I.; Williamson, D.F.; Gail, M.H. Excess deaths associated with underweight, overweight, and obesity. JAMA, 2005, 293, 1861-7.
4. National institutes of health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Obes. Res., 1998, 6, 51-209.
5. Maggard, M.A.; Shugarman, L.R.; Suttorp, M.; Maglione, M.; Sugerman, H.J.; Livingston, E.H.; Nguyen, N.T.; Li, Z.; Mojica, W.A.; Hilton, L.; Rhodes, S.; Morton, S. C.; Shekelle, P. G. Meta-analysis: surgical treatment of obesity. Ann. Intern. Med., 2005, 142, 547-559.
6. Mattar, S.S.; Velcu, L.M.; Rabinovitz, M.; Demetris, A. J. Surgically-Induced weight loss significantly improves nonalcoholic fatty liver disease and the Metabolic Syndrome. Ann. Surg., 2005, 242, 610-620.
7. North American Association for the Study of Obesity and the National Heart, Lung, and Blood Institute. The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. NIH, 2000, 00-4084.
8. Karlsson, J.; Taft, C.; Ryden, A.; Sjostrom, L.; Sullivan, M. Ten-year trends in health-related quality of life after surgical and conventional treatment for severe obesity: the SOS intervention study. Int. J. Obes., 2007, 31, 1248-61.
9. Sjöström, L.; Lindroos, AK.; Peltonen, M.; Torgerson, J.; Bouchard, C.; Carlsson, B.; Dahlgren, S.; Larsson, B.; Narbro, K.; Sjöström, C. D.; Sullivan, M.; Wedel, H. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N. Engl. J. Med., 2004, 351, 2683-93.
10. Buchwald, H.; Buchwald, J.N. Evolution of operative procedures for the management of morbid obesity 1950-2000. Obes. Surg., 2002, 12, 705-717.
11. Steinbrook, R.; Surgery for severe obesity. N. Engl. J. Med., 2004, 350, 1075-1079.
12. Pope, G.D.; Birkmeyer, J.D.; Finlayson, S.R. National trends in utilization and in-hospital outcomes of bariatric surgery. J. Gastrointest. Surg., 2002, 6, 855-60.
13. Santry, H.P.; Gillen, D.L.; Lauderdale, D. S. Trends in bariatric surgical procedures. JAMA, 2005, 294, 1909-1917.
14. Livingston, E. H. The incidence of bariatric surgery has plateaued in the U.S. Am. J. Surg., 2010, 200, 378-385.
15. Xanthakos, SA. Nutritional deficiencies in obesity and after bariatric surgery. Pediatr. Clin. North. Am., 2009, 56, 1105-1121.
16. Seaman, J.S.; Bowers, S. P.; Dixon, P.; Schindler, L. Dissolution of common psychiatric medications in a Roux-en-Y gastric bypass model. Psychosom., 2005, 46, 250-253.
17. Mirmiran, P.; Hosseini-Esfahanil, F.; Jessri, M.; Mahan, L. K.; Shiva, N.; Azizis, F.; Does dietary intake by Tehranian adults align with the 2005 dietary guidelines for Americans? Observations from the Tehran lipid and glucose study. J. Health. Popul. Nutr., 2011, 29, 39-52.
18. Caspary, W. F. Physiology and pathophysiology of intestinal absorption. Am. J. Clin. Nutr., 1992, 55, 299-308.
19. Levin, R.J. Digestion and absorption of carbohydrates - from molecules and membranes to humans. Am. J. Clin. Nutr., 1994, 59, 690-698.
20. Murray, R.K.; Kotlikoff, M. I. Receptor-activated calcium influx in human airway smooth muscle cells. J. Physiol., 1991, 435, 123-144.
21. Schanker, L. S. On the mechanism of absorption of drugs from the gastrointestinal tract. J. Med. Pharm. Chem., 1960, 2, 343-359.
22. Custodio, J. M.; Wu, C. Y.; Benet, L. Z.; Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv. Drug. Deliv. Rev., 2008, 60, 717-733.
23. Smith, A.; Henriksen, B.; Cohen, A. Pharmacokinetic considerations in Roux-en-Y gastric bypass patients. Am J. Health. Syst. Pharm., 2011, 68, 23, 2241-7.
24. Stenberg, P.; Luthman, K.; Artursson, P. Virtual screening of intestinal drug permeability. J. Control. Release, 2000, 65, 231-243.
25. Amidon, G. L.; Lennernas, H.; Shah, V. P.; Crison, J. R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res., 1995, 12, 413-420.
26. Dearden, J. C. Partitioning and lipophilicity in quantitative structure-activity relationships. Environ. Health. Perspect., 1985, 61, 203-228.
27. Martinez, M. N.; Amidon, G. L. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J. Clin. Pharmacol. 2002, 42, 620-643.
28. Ciarimboli, G. Organic cation transporters. Xenob., 2008, 38, 936-971.
29. Hagenbuch, B.; Meier, P. J. Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch, 2004, 447, 653-665.
30. Zimmerman, J. Methotrexate transport in the human intestine. Evidence for heterogeneity. Biochem. Pharmacol., 1992, 43, 2377-2383.
31. Duverne, C.; Bouten, A.; Deslandes, A.; Westphal, J.F.; Trouvin, J. H.; Farinotti, R.; Carbon, C.; Modification of cefixime bioavailability by nifedipine in humans: involvement of the dipeptide carrier system. Antimicrob. Agents. Chemother., 1992, 36, 2462-2467.
32. Westphal, J. F.; Trouvin, J. H.; Deslandes, A.; Carbon, C. Nifedipine enhances amoxicillin absorption kinetics and bioavailability in humans. J. Pharmacol. Exp. Ther., 1990, 255, 312-317.
33. Wang, D. S.; Kusuhara, H.; Kato, Y.; Jonker, J. W.; Schinkel, A. H.; Sugiyama, Y. Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. Mol. Pharmacol., 2003, 63, 844-848.
34. Bourdet, D. L.; Pritchard, J. B.; Thakker, D. R. Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J. Pharmacol. Exp. Ther., 2005, 315, 1288-1297.
35. Mouly, S.; Paine, M. F. P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm. Res., 2003, 20, 1595-1599.
36. Saitoh, H., Aungst, B. J. Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine. Pharm. Res., 1995, 12, 1304-1310.
37. Benet, L. Z.; Zia-Amirhosseini, P. Basic principles of pharmacokinetics. Toxicol. Pathol., 1995, 23, 115-123.
38. Wu, C. Y.; Benet, L. Z. Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res., 2005, 22, 11-23.
39. Requarth, J. A.; Burchard, K. W.; Colacchio, T. A.; Stukel, T. A. Long-term morbidity following jejunoileal bypass. The continuing potential need for surgical reversal. Arch. Surg., 1995, 130, 318-25.
40. Mole, D. R.; Tomson, C. R.; Mortensen, N.; Winearls, C. G. Renal complications of jejuno-ileal bypass for obesity. QJM, 2001, 94, 69-77.
41. Padwal, R.; Brocks, D.; Sharma, A. M. A systematic review of drug absorption following bariatric surgery and its theoretical implications. Obes. Rev., 2010, 11, 41-50.
42. Fontana, M. A.; Wohlgemuth, S. D. The surgical treatment of metabolic disease and morbid obesity. Gastroenterol. Clin. North. Am., 2010, 39, 125-133.
43. Nocca, D.; Krawczykowsky, D.; Bomans, B.; Noël, P.; Picot, M. C.; Blanc, P. M.; De Seguin, C.; Millat, B.; Gagner, M.; Monnier, L.; Fabre, J. M. A prospective multicenter study of 163 sleeve gastrectomies: results at 1 and 2 years. Obes. Surg., 2008, 18, 560-565.
44. DeMaria, E.J. Bariatric surgery for morbid obesity. N. Engl. J. Med., 2007, 356, 2176-2183.
45. Franco, J.V.; Ruiz, P. A.; Palermo, M.; Gagner, M. A Review of Studies Comparing Three Laparoscopic Procedures in Bariatric Surgery: Sleeve Gastrectomy, Roux-en-Y Gastric Bypass and Adjustable Gastric Banding. Obe Surg., 2011, 21, 1458-1468.
46. Gumbs, A. A.; Gagner, M.; Dakin, G.; Pomp, A. Sleeve gastrectomy for morbid obesity. Obes. Surg., 2007, 17, 962-969.
47. Ward, M.; Prachand, V. Surgical treatment of obesity. Gastrointest. Endosc., 2009, 70, 985-990.
48. Smith, B. R.; Schauer, P.; Nguyen, N. T. Surgical approaches to the treatment of obesity: bariatric surgery. Endocrinol. Metab. Clin. North. Am., 2008, 37, 943-964.
49. Truesdell, D. D.; Whitney, E. N.; Acosta, P. B. Nutrients in vegetarian foods. J. Am. Diet. Assoc., 1984, 84, 28-35.
50. Hess, D. S.; Hess, D. W. Biliopancreatic diversion with a duodenal switch. Obes. Surg., 1998, 8, 267-282.
51. Marceau, P.; Hould, F. S.; Simard, S.; Lebel, S.; Bourque, R. A.; Potvin, M.; Biron, S. Biliopancreatic diversion with duodenal switch. World. J. Surg., 1998, 22, 947-954.
52. DeMeester, T. R.; Fuchs, K. H.; Ball, C. S.; Albertucci, M.; Smyrk, T. C.; Marcus, J. N. Experimental and clinical results with proximal end-to-end duodenojejunostomy for pathologic duodenogastric reflux. Ann. Surg., 1987, 206, 414-426.
53. Kant, A. K. Consumption of energy-dense, nutrient-poor foods by adult Americans: nutritional and health implications. The third National Health and Nutrition Examination Survey, 1988-1994. Am. J. Clin. Nutr., 2000, 72, 929-936.
54. Puglisi, M. J.; Fernandez, M. L. Modulation of C-reactive protein, tumor necrosis factor-alpha, and adiponectin by diet, exercise, and weight loss. J. Nutr., 2008, 138, 2293-2296.
55. O'Rourke R. W. Inflammation in obesity-related diseases. Surg., 2009, 145, 255-259.
56. Morínigo, R.; Casamitjana, R.; Delgado, S.; Lacy, A.; Deulofeu, R.; Conget, I.; Barceló-Batllori, S.; Gomis, R.; Vidal, J. Insulin resistance, inflammation, and the metabolic syndrome following Roux-en-Y gastric bypass surgery in severely obese subjects. Diab. Care, 2007, 30, 1906-1908.
57. Munoz, M.; Mazure, R. A.; Culebras, J. M. Obesity and the immune system. Nutr. Hosp., 2004, 19, 319-324.
58. Schweiger, C.; Keidar, A. Nutritional deficiencies in bariatric surgery patients: prevention, diagnosis and treatment. Harefuah, 2010, 149, 715-20.
59. Gracia, J.A., Martinez, M.; Aguilella, V. Postoperative morbidity of biliopancreatic diversion depending on common limb length. Obes. Syrg., 2007, 17, 1306-1311.
60. Xanthakosa, S. A.; Thomas, I. H. Nutritional consequences of bariatric surgery. Curr. Opin. Clin. Nutr. Metab. Care, 2006, 9, 489-96.
61. Rudnicki, S. A. Prevention and treatment of peripheral neuropathy after bariatric surgery. Curr. Treat Options Neurol., 2010, 12, 29-36.
62. Chaston, T. B.; Dixon, J. B.; O'Brien, P. E. Changes in fat-free mass during significant weight loss: a systematic review. Int. J. Obes., 2007, 31, 743-750.
63. Flancbaum, L.; Belsley, S.; Drake, V.; Colarusso, T.; Tayler, E. Preoperative nutritional status of patients undergoing Roux-en-Y gastric bypass for morbid obesity. J. Gastrointest. Surg., 2006, 10, 1033-1037.
64. Looker, A. C.; Dawson-Hughes, B.; Calvo, M. S.; Gunter, E. W.; Sahyoun, N. R. Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. Bone, 2002, 30, 771-777.
65. Seres, D. S. Surrogate nutrition markers, malnutrition, and adequacy of nutrition support. Nutr. Clin. Pract. 2005, 20, 308-313.
66. Fuhrman, M. P. The albumin-nutrition connection: separating myth from fact. Nutrition, 2002, 18, 199-200.
67. Mechanick, J. I.; Kushner, R. F.; Sugerman, H. J.; Gonzalez-Campoy, J. M.; Collazo-Clavell, M. L.; Spitz, A. F.; Apovian, C. M.; Livingston, E. H.; Brolin, R.; Sarwer, D. B.; Anderson, W. A.; Dixon, J.; Guven, S. American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery medical guidelines for clinical practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient. Obesity, 2009, 17, 1, 70.
68. Aills, L.; Blankenship, J.; Buffington, C. ASMBS Allied Health Nutritional Guidelines for the Surgical Weight Loss Patient. Surg. Obes. Relat. Dis., 2008, 4, 73-108.
69. Amaral, J. F.; Thompson, W. R.; Caldwell, M. D.; Martin, H. F.; Randall, H. T. Prospective hematologic evaluation of gastric exclusion surgery for morbid obesity. Ann. Surg., 1985, 201, 186-93.
70. Halverson, J. D.; Zuckerman, G. R.; Koehler, R. E.; Gentry, K.; Michael, H. E.; DeSchryver-Kecskemeti, K. Gastric bypass for morbid obesity: a medical-surgical assessment. Ann. Surg., 1981, 194, 152-160.
71. Ruz, M.; Carrasco, F.; Rojas, P.; Codoceo, J. Iron absorption and iron status are reduced after Roux-en-Y gastric bypass. Am. J. Clin. Nutr., 2009, 90, 527-532.
72. Kushner, R. F. Micronutrient deficiencies and bariatric surgery. Curr. Opin. Endocrinol. Diabetes Obes., 2006, 13, 405-411.
73. Davies, D. J.; Baxter, J.M.; Baxter, J. N. Nutritional deficiencies after bariatric surgery. Obes. Surg., 2007, 17, 1150-1158.
74. Avgerinos, D. V.; Llaguna, O. H.; Seigerman, M.; Lefkowitz, A. J.; Leitman, I. M. Incidence and risk factors for the development of anemia following gastric bypass surgery. World J. Gastroenterol., 2010, 16, 1867-1870.
75. Rhode, B. M.; Shustik, C.; Christou, N. V.; MacLean, L. D. Iron absorption and therapy after gastric bypass. Obes. Surg., 1999, 9, 17-21.
76. Bal, B.; Koch, T. R.; Finelli, F. C.; Sarr, M. G. Managing medical and surgical disorders after divided Roux-en-Y gastric bypass surgery. Nat. Rev. Gastroenterol., Hepatol., 2010, 7, 320-334.
77. Alvarez-Leite, J. I. Nutrient deficiencies secondary to bariatric surgery. Curr. Opin. Clin. Nutr. Metab. Care, 2004, 7(5), 569-75.
78. Avgerinos, D. V.; Llaguna, O. H.; Seigerman, M.; Lefkowitz, A. J. Incidence and risk factors for the development of anemia following gastric bypass surgery. World J. Gastroenterol. 2010, 16, 1867-1870.
79. Goldner, W. S.; Stoner, J. A.; Thompson, J.; Taylor, K.; Larson, L.; Erickson, J.; McBride, C. Prevalence of vitamin D insufficiency and deficiency in morbidly obese patients: a comparison with non-obese controls. Obes. Surg., 2008, 18, 145-150.
80. Gemmel, K.; Santry, H. P.; Prachand, V. N.; Alverdy, J. C. Vitamin D deficiency in preoperative bariatric surgery patients. Surg. Obes. Relat. Dis., 2009, 5, 54-59.
81. Brouwer, D. A.; Van Beek, J.; Ferwerda, H.; Brugman, A. M.; Van Der Klis, F. R.; Van Der Heiden, H. J.; Muskiet, F. A. Rat adipose tissue rapidly accumulates and slowly releases an orally-administered high vitamin D dose. Br. J. Nutr., 1998, 79, 527-532.
82. Bell, N. H.; Epstein, S.; Shary, J.; Greene, V.; Oexmann, M. J.; Shaw, S. Evidence for alteration of the vitamin D-endocrine system in obese subjects. J. Clin. Invest., 1985, 76, 370-373.
83. Lin, E.; Armstrong-Moore, D.; Liang, Z.; Sweeney, J. F.; Torres, W. E.; Ziegler, T. R. Contribution of adipose tissue to plasma 25-hydroxyvitamin D concentrations during weight loss following gastric bypass surgery. Obesity, 2011, 19(3), 588-594.
84. Slater, G. H.; Ren, C. J.; Siegel, N.; Williams, T.; Barr, D.; Wolfe, B.; Dolan, K.; Fielding, G. A. Serum fat-soluble vitamin deficiency and abnormal calcium metabolism after malabsorptive bariatric surgery. J. Gastrointest. Surg., 2004, 8, 48-55.
85. Newbury, L.; Dolan, K.; Hatzifotis, M.; Fielding, G. Calcium and vitamin D depletion and elevated parathyroid hormone following biliopancreatic diversion. Obes. Surg., 2003, 13, 893-895.
86. Ducloux, R.; Nobecourt, E.; Chevallier, J. M.; Ducloux, H.; Elian, N.; Altman, J. J. Vitamin D deficiency before bariatric surgery: should supplement intake be routinely prescribed? Obes. Surg., 2011, 21, 556-560.
87. Sakhaee, K.; Bhuket, T.; Adams-Huet, B.; Rao, D. S. Meta-analysis of calcium bioavailability: a comparison of calcium citrate with calcium carbonate. Am. J. Ther., 1999, 6, 313-21.
88. Marcuard, S. P.; Sinar, D. R.; Swanson, M. S.; Silverman, J. F.; Levine, J. S. Absence of luminal intrinsic factor after gastric bypass surgery for morbid obesity. Dig. Dis. Sci., 1989, 34, 1238-1242.
89. Behrns, K. E.; Smith, C. D.; Sarr, M. G. Prospective evaluation of gastric acid secretion and cobalamin absorption following gastric bypass for clinically severe obesity. Dig. Dis. Sci., 1994, 39(2), 315-320
90. Brolin, R. E.; LaMarca, L. B.; Kenler, H. A.; Cody, R. P. Malab-sorptive gastric bypass in patients with superobesity. J. Gastrointest. Surg., 2002, 6, 195-203.
91. Ledoux, S.; Msika, S.; Moussa, F.; Larger, E. Comparison of nutritional consequences of conventional therapy of obesity, adjustable gastric banding, and gastric bypass. Obes. Surg., 2006, 16(8), 1041-1049.
92. Rhode, B. M.; Arseneau, P.; Cooper, B. A.; Katz, M. Vitamin B-12 deficiency after gastric surgery for obesity. Am. J. Clin. Nutr., 1996, 63(1), 103-109.
93. Provenzale, D.; Reinhold, R. B.; Golner, B.; Irwin, V. Evidence for diminished B12 absorption after gastric bypass: oral supplementation does not prevent low plasma B12 levels in bypass patients. J. Am. Coll. Nutr., 1992, 11, 1, 29-35.
94. Skroubis, G., Sakellaropoulos, G., Pouggouras, K., Mead, N., Nikiforidis, G. Comparison of nutritional deficiencies after Rouxen-Y gastric bypass and after biliopancreatic diversion with Rouxen-Y gastric bypass. Obes. Surg., 2002, 12, 4, 551-558.
95. Gasteyger, C.; Suter, M.; Calmes, J. M.; Gaillard, R. C.; Giusti, V. Changes in body composition, metabolic profile, and nutritional status 24 months after gastric banding. Obes. Surg., 2006, 16, 243-250.
96. Sobieraj, D. M.; Wang, F.; Kirton, O. C. Warfarin resistance after total gastrectomy and Roux-en-Y esophagojejunostomy. Pharmacotherapy, 2008, 28, 1537-1541.
97. Griffiths, T. M.; Thomas, P.; Campbell, I. A. Antituberculosis drug levels after jejunoileal bypass. Br. J. Dis. Chest, 1982, 76, 286-289.
98. Mallory, G. N.; Macgregor, A. M. Folate status following gastric bypass surgery (the Great Folate Mystery). Obes. Surg., 1991, 1, 69-72.
99. Boylan, L. M.; Sugerman, H. J.; Driskell, J. A. Vitamin E, vitamin B-6, vitamin B-12, and folate status of gastric bypass surgery patients. J. Am. Diet Assoc., 1988, 88, 579-585.
100. Hatizifotis, M.; Dolan, K.; Newbury, L.; Fielding, G. Symptomatic vitamin A deficiency following biliopancreatic diversion. Obes. Surg., 2003, 13, 655-657.
101. Quaranta, L.; Nascimbeni, G.; Semeraro, F.; Quaranta, C. A. Severe corneoconjunctival xerosis after biliopancreatic bypass for obesity (Scopinaro's operation). Am. J. Ophthalmol., 1994, 118, 817-818.
102. Van Mieghem, T.; Van Schoubroeck, D.; Depiere, M.; Debeer, A. Fetal cerebral hemorrhage caused by vitamin K deficiency after complicated bariatric surgery. Obstet. Gynecol., 2008, 112, 434-6.
103. Kang, L.; Marty, D.; Pauli, R. M.; Mendelsohn, N. J.; Prachand, V. Chondrodysplasia punctata associated with malabsorption from bariatric procedures. Surg. Obes. Relat. Dis., 2010, 6, 1, 99-101.
104. Moize, V.; Geliebter, A.; Gluck, M. E.; Yahav, E.; Lorence, M.; Colarusso, T.; Drake, V.; Flancbaum, L. Obese patients have inadequate protein intake related to protein intolerance up to 1 year following Roux-en-Y gastric bypass. Obes. Surg., 2003, 13, 1, 23-28.
105. Scopinaro, N.; Marinari, G. M.; Pretolesi, F.; Papadia, F.; Murelli, F.; Marini, P.; Adami, G. F. Energy and nitrogen absorption after biliopancreatic diversion. Obes. Surg., 2000, 10, 5, 436-441.
106. Skroubis, G.; Anesidis, S.; Kehagias, I.; Mead, N.; Vagenas, K.; Kalfarentzos, F. Roux-en-Y gastric bypass versus a variant of biliopancreatic diversion in a non-superobese population: prospective comparison of the efficacy and the incidence of metabolic deficiencies. Obes. Surg., 2006, 4, 488-495.
107. Nanni, G.; Balduzzi, G. F.; Capoluongo, R.; Scotti, A.; Rosso, G.; Botta, C.; Demichelis, P.; Daffara, M.; Coppo, E. Biliopancreatic diversion: clinical experience. Obes. Surg., 1997, 7, 26-29.
108. Malone, M. Altered drug disposition in obesity and after bariatric surgery. Nutr. Clin. Pract., 2003, 18, 131-135
109. Kennedy, M. C.; Wade, D. N. Phenytoin absorption in patients with ileojejunal bypass. Br. J. Clin. Pharmacol., 1979, 7, 515-518.
110. Peterson, D. I. Phenytoin absorption following jejunoileal bypass. Bull. Clin. Neurosci., 1983, 48, 148-149.
111. Prince, R. A., Pincheira, J. C.; Mason, E. E.; Printen, K. J. Influence of bariatric surgery on erythromycin absorption. J Clin Pharmacol, 1984, 24, 523-527.
112. Kampmann, J. P.; Klein, H.; Lumholtz, B.; Molholm, J. E. Ampicillin and propylthiouracil pharmacokinetics in intestinal bypass patients followed up to a year after operation. Clin. Pharmacokinet., 1984, 9, 168-176.
113. Magee, S. R.; Shih, G.; Hume, A. Malabsorption of oral antibiotics in pregnancy after gastric bypass surgery. J. Am. Board Fam. Med., 2007, 20, 310-313.
114. Chenhsu, R. Y.; Wu, Y.; Katz, D.; Rayhill, S. Dose-adjusted cyclosporine c2 in a patient with jejunoileal bypass as compared to seven other liver transplant recipients. Ther. Drug. Monit., 2003, 25, 665-670.
115. Kelley, M.; Jain, A.; Kashyap, R.; Orloff, M.; Abt, P.; Wrobble, K.; Venkataramanan, R.; Bozorgzadeh, A. Change in oral absorption of tacrolimus in a liver transplant recipient after reversal of jejunoileal bypass: case report. Transplant Proc., 2005, 37, 3165-3167.
116. Andersen, A. N.; Lebech, P. E.; Sorensen, T. I.; Borggaard, B. Sex hormone levels and intestinal absorption of estradiol and Dnorgestrel in women following bypass surgery for morbid obesity. Int. J. Obes., 1982, 6, 91-96.
117. Victor, A.; Odlind, V.; Kral, J. G. Oral contraceptive absorption and sex hormone binding globulins in obese women: effects of je-junoileal bypass. Gastroenterol. Clin. North Am., 1987, 16, 483-491.
118. Wills, S. M.; Zekman, R.; Bestul, D.; Kuwajerwala, N.; Decker, D. Tamoxifen malabsorption after Roux-en-Y gastric bypass surgery: case series and review of the literature. Pharmacotherapy, 2010, 30, 217.
119. Werbin, N. Tuberculosis after jejuno-ileal bypass for morbid obesity. Postgrad. Med. J., 1981, 57, 252-253.
120. Marcus, F. I.; Quinn, E. J.; Horton, H.; Jacobs, S.; Pippin, S.; Stafford, M.; Zukoski, C. The effect of jejunoileal bypass on the pharmacokinetics of digoxin in man. Circulation, 1977, 55, 537-541.
121. Terry, S. I.; Gould, J. C.; McManus, J. P.; Prescott, L. F. Absorption of penicillin and paracetamol after small intestinal bypass surgery. Eur. J. Clin. Pharmacol., 1982, 23, 245-248.
122. Food and Drug Administration. Guidance for Industry: Waiver of In vivo Bioavailability and Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. Food and Drug Administration, 2000.
123. Skottheim, I. B.; Stormark, K.; Christensen, H.; Jakobsen, G. S. Significantly altered systemic exposure to atorvastatin acid following gastric bypass surgery in morbidly obese patients. Clin. Pharmacol. Ther., 2009, 86, 3, 311-8.
124. Skottheim, I.B.; Stormark, K.; Christensen, H.; Jakobsen, G. S. Significant increase in systemic exposure of atorvastatin after biliopancreatic diversion with duodenal switch. Clin. Pharmacol. Ther., 2010, 87, 6, 699-705.